Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01000506 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 621
- Enrollment target
NCT01000506 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 621 participants.
The verdict
NCT01000506, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 621 participants
- Enrollment target
Study Summary
The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma medications. The study will look at different doses of mepolizumab in comparison to a placebo.
Interventions
- DRUG Placebo saline
- BIOLOGICAL Mepolizumab 750
- BIOLOGICAL Mepolizumab 250
- BIOLOGICAL Mepolizumab 75
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 621 participants |
| Start Date | 2009-11-01 |
| Est. Completion | 2012-03-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01000506
The ClinicalTrials.gov registry entry for NCT01000506 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 621 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo saline is the first listed.
NCT01000506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01000506 about?
NCT01000506 is a clinical study titled "Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma". The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma medications. The study will look at different doses of mepolizumab in comp...
What is the current status of trial NCT01000506?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 621 participants. The study started on 2009-11-01. Estimated completion is 2012-03-23.
What interventions are being tested in trial NCT01000506?
The interventions under investigation include: Placebo saline (DRUG), Mepolizumab 750 (BIOLOGICAL), Mepolizumab 250 (BIOLOGICAL), Mepolizumab 75 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01000506?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.